You should not treat BPC-157 as a routine over-the-counter medicine. It is an investigational synthetic peptide with limited human evidence, and an online listing cannot answer key questions about quality, safety, diagnosis, or whether it fits your health situation. BPC-157 does not have an established FDA-approved medicine for injury-recovery uses. A licensed clinician can help separate an injury-care plan from marketing claims. 1 2 3
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →Can you buy BPC-157 over the counter?
Not in the way people usually mean “over the counter.” An OTC medicine has an established consumer-use framework, including labeling and directions designed for self-selection. An online BPC-157 listing is simply a listing; it does not establish that the product is suitable for self-treatment of a muscle strain, tendon injury, knee pain, or another condition. 2 3
Why an online listing is not the same as an established OTC medicine
Online peptide sellers may use terms such as “research use,” “laboratory grade,” or “not for human consumption.” Those phrases are not medical-treatment instructions, and they do not replace a diagnosis, product-quality controls, or follow-up care. Sports-medicine reviews describe major evidence and safety gaps around unapproved peptide therapies used for injury and performance claims. 2 5
What this article can verify—and what needs current confirmation
The research record supports a cautious conclusion: BPC-157 has limited human clinical evidence and ongoing or planned research, not established proof for common injury-recovery claims. Regulatory and compounding rules can change, so readers should check current FDA information and discuss individual access questions with a licensed clinician rather than relying on seller claims. 2 7 8
What are the quick facts about BPC-157?
BPC-157 is short for Body Protection Compound 157, also called PL 14736 in some research discussions. It is an investigational synthetic pentadecapeptide, meaning it is made of 15 amino acids. It does not have an established approved brand name or an established generic INN presented as a standard OTC medicine. 1 2
| Access path | What it can tell you | What it cannot tell you |
|---|---|---|
| Online research-peptide listing | That a seller is advertising a product | Whether the product is clinically appropriate, accurately labeled, sterile, or effective for an injury |
| Registered clinical trial | That a study is recruiting, pending, completed, or otherwise listed | Whether BPC-157 has been proven safe or effective |
| Clinician-reviewed care | Whether a licensed provider considers treatment appropriate for an individual | A guaranteed prescription or outcome |
| Chia BPC-157 injection | That Chia offers provider-reviewed compounded injection shipped from a state-licensed 503A pharmacy | FDA approval of a compounded medication or a guaranteed result |
What is BPC-157, and what is it studied for?
BPC-157 is discussed in peptide literature because animal and laboratory studies have examined tissue healing, inflammation signaling, blood-vessel signaling, and digestive-system effects. Most of that evidence is preclinical, which means it cannot show that the same effects occur in people with musculoskeletal injuries. 1 5
Why injury and recovery claims are common online
Muscle strain, tendon injury, cartilage damage, and post-surgical recovery are frustrating problems with uncertain timelines. That makes simple recovery claims appealing. But a proposed mechanism—such as changes in angiogenesis or inflammatory signaling in a laboratory model—is not proof that a peptide improves human recovery, pain, return to activity, or surgical outcomes. 1 6
What preclinical mechanisms do not prove
Animal and cell studies can help researchers decide what to test next. They cannot establish the right patient population, route, dose, timing, side-effect profile, or long-term safety in people. That gap matters because injury symptoms may also reflect a fracture, tendon rupture, infection, nerve problem, or another condition that needs prompt evaluation. 2 3
What does human research on BPC-157 actually show?
The honest answer is that human clinical evidence remains limited. A published report described intra-articular BPC-157 use for multiple types of knee pain, but it was not the kind of large, controlled trial needed to establish routine safety or effectiveness. Individual results vary, and this report cannot prove that BPC-157 caused the outcomes described. 4
The published knee-pain report
Lee and Padgett published a 2021 report on intra-articular BPC-157 for multiple forms of knee pain. It is useful as an early clinical observation, but it does not settle questions about comparative benefit, adverse effects, optimal use, or results in other injuries. 4
Registered studies in muscle strain and rotator cuff repair
ClinicalTrials.gov lists a recruiting Phase 2 study of BPC-157 for acute hamstring muscle-strain repair with a planned enrollment of 120 participants. It also lists a not-yet-recruiting Phase 1 study after rotator cuff repair with a planned enrollment of 30 participants. These listings show active research interest, not established treatment benefit. 7 8
A separate Phase 1 safety and pharmacokinetics record, PCO-02, is listed with unknown status and planned enrollment of 42. A registry entry alone does not provide a completed study’s results or establish safety. 9
3-min quiz
Talk with a clinician about your recovery goals
Chia currently offers compounded BPC-157 injection through an online, licensed-provider review. A medical evaluation is required, and a prescription is not guaranteed. Medications are compounded by US state-licensed 503A pharmacies and shipped to your door; compounded medications are not FDA-approved.
Why should patients be cautious about products marketed as BPC-157?
The central issue is not whether a product page looks professional. It is whether the product’s identity, concentration, purity, handling, labeling, and—when relevant—sterility can be trusted, and whether use is being guided by a clinician who understands the person’s injury and medical history. Product quality and diagnosis both matter when a person is considering an injectable peptide. 2 3
- Do not use social-media testimonials as proof of effectiveness. Personal stories cannot control for diagnosis, natural healing, rehabilitation, placebo effects, or other treatments. 2
- Be wary of claims that a peptide can replace a careful exam, imaging when needed, rehabilitation, or surgery evaluation. Reviews of unapproved peptide therapies emphasize the evidence gap. 2 5
- Seek urgent care for an inability to bear weight, a visibly deformed joint, sudden weakness, numbness, fever with a painful swollen joint, chest pain, or shortness of breath. These symptoms can signal problems that need prompt assessment. 3
How can you evaluate an online peptide seller or access claim?
Start by asking whether the claim gives you enough information to make a safe health decision. A legitimate clinical path includes a medical review, not just a checkout page. For more detail, see our guides on finding a legitimate peptide source, what “research-only” means, and where to get peptide injections safely.
- 1Ask what condition is actually being evaluated and whether an exam, imaging, physical therapy, or specialist referral may be more appropriate.
- 2Ask what human evidence supports the specific claim—not only animal studies or testimonials.
- 3Ask who is responsible for clinical review, follow-up, and questions about side effects.
- 4Ask where the medication is compounded and whether the pharmacy is state licensed.
- 5Avoid sellers that offer self-treatment instructions without a meaningful medical evaluation. 2 3
How does Chia offer BPC-157 care?
At Chia, BPC-157 injection starts from $115 per month and is available only after an online health questionnaire and review by a licensed US provider. Our providers prescribe only when clinically appropriate, so a prescription is never guaranteed. Plans and current pricing are available on our BPC-157 treatment page.
When treatment is prescribed, medication is compounded in the United States by a state-licensed 503A compounding pharmacy and shipped to the patient’s door. Dosing is provider-guided and can be adjusted over time, with portal access to the care team between visits. Compounded medications are not FDA-approved, and outcomes for compounded BPC-157 are not established by FDA-reviewed clinical data.
What peptides stack well with BPC-157?
BPC-157 is sometimes discussed alongside other recovery-focused peptides, but there are no established combination-specific human trials showing that a stack is safe or effective for injury recovery. A clinician should review the diagnosis, medication list, medical history, and the limits of the evidence before considering any combined approach. 2 5
BPC-157 and TB-500
BPC-157 and TB-500 are commonly combined in research and compounding discussions because both are marketed around tissue-repair mechanisms. The safety caveat is important: combination-specific human evidence is lacking, and TB-500 is not part of Chia’s current public treatment catalog. 2 5
BPC-157 and GHK-Cu
GHK-Cu is studied for signaling related to skin and connective tissue, which is why it may appear in recovery or skin-health discussions. Chia offers GHK-Cu cream, not an injectable GHK-Cu product; there are no adequate combination trials establishing benefits or risks of using it with BPC-157 for an injury. 5 6
What questions should you ask a clinician about an injury or recovery concern?
A clinician can help you focus on the problem that needs care rather than the product that is easiest to find online. Early diagnosis can change the care plan, especially after a sudden injury or after surgery. 3
- What is the most likely diagnosis, and do I need an in-person exam, imaging, or referral?
- What symptoms would mean I need urgent or emergency care?
- What established treatment options fit this injury and my health history?
- What does the human evidence say about BPC-157 for my specific concern?
- Would a registered clinical trial be a reasonable option to discuss? 7 8
3-min quiz
Start with a clinician-reviewed visit
If you want to discuss BPC-157 or another Chia treatment, start with our online health questionnaire. A licensed US provider reviews eligibility and prescribes only when clinically appropriate; a prescription is not guaranteed. Chia medications are compounded by state-licensed 503A pharmacies, and compounded medications are not FDA-approved.
Frequently asked questions about buying BPC-157
BPC-157 should not be treated as a routine OTC medicine. An online listing does not establish that a product is appropriate for self-treatment, accurately labeled, or supported by strong human evidence.
No. Reviews and testimonials cannot control for natural healing, diagnosis, rehabilitation, placebo effects, other treatments, or product quality. 2
Yes. Chia currently offers compounded BPC-157 injection after a licensed US provider reviews a patient’s health information. A prescription is not guaranteed, and compounded medications are not FDA-approved.
Seek a clinician’s evaluation, especially for severe pain, inability to bear weight, deformity, sudden weakness, numbness, fever, or a painful swollen joint. A clinician can assess the injury and discuss evidence-based treatment options. 3
References
- 1.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019.
- 2.Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026.
- 3.Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine. 2026.
- 4.Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021.
- 5.Rahman OF, Lee SJ, Seeds WA. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews. 2026.
- 6.DeFoor MT, Dekker TJ. Injectable Therapeutic Peptides—An Adjunct to Regenerative Medicine and Sports Performance? Arthroscopy. 2025.
- 7.ClinicalTrials.gov. BPC 157 for Acute Hamstring Muscle Strain Repair (NCT07437547). 2026.
- 8.ClinicalTrials.gov. Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery (NCT07803250). 2026.
- 9.ClinicalTrials.gov. PCO-02: Safety and Pharmacokinetics Trial (NCT02637284). 2026.
- 10.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting materials and docket, July 23–24, 2026. 2026.
- 11.STAT. Pharmacy Compounding Advisory Committee vote on nominated peptide substances, including BPC-157. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.


